Sorry, you need to enable JavaScript to visit this website.

This site is intended only for healthcare professionals resident in the United Kingdom

Prescribing information can be found at the bottom of the page

The management of invasive candidiasis

  1. Invasive candidiasis is an additional and significant problem in ICU and haematology patients1-4
  2. Patients in the ICU have an increased risk of developing candidaemia compared with patients on medical or surgical wards4
    1. 40.2% of candidaemia occurs in the ICU5
  3. Delaying antifungal therapy can have fatal consequences4,6
  4. Comorbidities and the potential for multiple drug interactions from concomitant medications complicate treatment1,7,8
     

Mortality rate stratified by delay in initiation of antifungal therapy*6

Full preview Mortality rate stratified by delay in initiation of antifungal therapy

Adapted from Morrell et al 20056

A single-centre, retrospective, US cohort analysis of all hospitalised patients with a positive blood culture for Candida between January 2001 and December 2004. Candida bloodstream infection was identified in 157 patients. The goals of the study were to determine the prevalence of delay in empiric antifungal treatment until after blood culture results were known and the effect of this delay on clinical outcomes6

ICU, intensive care unit

References


    1.     Najman A, et al. Bull Cancer 2009;96:563-570.
    2.     Murali S, Langston A. Transpl Infect Dis 2009;11:480-490.
    3.     Gamaletsou MN, et al. Clin Microbiol Infect 2014;20:050-057.
    4.     Delaloye J. Calandra T. Virulence 2014;5:154-162.
    5.     Tortorano AM, et al. ECMM Working Group on Candidaemia. Eur J Clin Microbiol Infect Dis
            2004; 23:317-322.
    6.     Morrell M, et al. Antimicrob Agents Chemother 2005; 49:3640-3645.
    7.     Papadopoulous J. Smithburger PL. Crit Care Med 2010; 38 Suppl 6: S126-135.
    8.     Perazella MA. Kidney Int 2012; 81:1172-1178.